Answers are grounded in this paper and cite their sources.
OBJECTIVE: To analyze the HRQoL loss associated with self-perceived anxiety/depression in patients with seropositive rheumatoid arthritis (RA). METHOD: This secondary data analysis is based on a registry-based retrospective follow-up study of patients with seropositive RA treated between August 2014 and January 2023 in ARTMEDICA, Colombia. HRQoL loss and self-perceived anxiety/depression were defined as outcomes. Disease activity (DAS-28) and other patient data were also gathered. Statistical analyses were performed using the ordinal logistic and generalized linear regression models. RESULTS: A total of 3579 patients with a mean follow-up of 2.9 (SD 2.4) years, 85.6% women with a median age at diagnosis of 48.1 (IQR 37.8-57.5) years, and a median of 6.5 (IQR 1.9-14.7) years living with RA were included. At program admission, the median DAS-28 score was 2.8 (IQR 2.1-4.2), and 6.6% of patients reported extreme anxiety/depression. The average HRQoL loss was 3.4 months per year lived with seropositive AR. Among patients with no pain or discomfort, moderate and extreme anxiety/depression were associated with mean HRQoL losses of 2.2 (95% CI - 2.3 to - 2.2) and 4.1 (95% CI - 4.3 to - 3.8) months. In patients with extreme pain/discomfort, these estimations were 0.8 (95% CI - 0.9 to - 0.7) and 1.9 (95% CI - 2.1 to - 1.7) months, respectively. CONCLUSION: Our study adds to the available body of evidence by clarifying the differential impact of anxiety/depression on HRQoL, depending on the severity of pain. These findings highlight the importance of strengthening mental health care and psychological well-being interventions for patients with RA, regardless of pain or disease activity. Key Points • The average HRQoL loss was 3.4 months per year lived with seropositive AR. • Pain/discomfort rather than disease activity explained the severity of anxiety/depression as well as its associated HRQoL loss. • For patients with extreme pain/discomfort and anxiety/depression, the average HRQoL loss was 8.1 months per year lived with the disease compared to 0.4 months for patients without those impacts.
No takes yet. Share an insight, caveat, or question.
Rojas‐Gualdrón et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: